Invention Grant
- Patent Title: Morpholinylquinazolines
- Patent Title (中): 吗啉基喹唑啉
-
Application No.: US13581699Application Date: 2011-02-17
-
Publication No.: US09126952B2Publication Date: 2015-09-08
- Inventor: Werner Mederski , Thomas Fuchss , Frank Zenke
- Applicant: Werner Mederski , Thomas Fuchss , Frank Zenke
- Applicant Address: DE Darmstadt
- Assignee: Merck Patent GmbH
- Current Assignee: Merck Patent GmbH
- Current Assignee Address: DE Darmstadt
- Priority: DE102010011493 20100316
- International Application: PCT/EP2011/000767 WO 20110217
- International Announcement: WO2011/113512 WO 20110922
- Main IPC: A61K31/5377
- IPC: A61K31/5377 ; A61K31/55 ; A61K35/00 ; C07D409/06 ; C07D413/14 ; C12N5/09 ; C07D239/94 ; C07D239/86 ; C07D295/155 ; C07D401/04 ; C07D401/14 ; C07D409/14 ; C07D417/06 ; C07D417/14

Abstract:
The invention relates to compounds of the formulae (I), (II) and (III) in which R1, R2, R3, R4, Y, W1, W2, L, A, Alk, Cyc, Ar, Het1, Het2, Hal and n have the meaning indicated in Claim 1, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumors, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of their salts.
Public/Granted literature
- US20130012489A1 Morpholinylquinazolines Public/Granted day:2013-01-10
Information query
IPC分类: